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Abstract
Genome-wide sequencing studies in pediatric cancer cohorts indicate that about 10% of patients have germline mutations within
cancer predisposition genes. Within this group, primary immune deficiencies take the priority regarding the vulnerability of the
patients to infectious agents and the difficulties of cancer management. On the other hand, early recognition of these diseases may
offer specific targeted therapies and hematopoietic stem cell transplantation as an option. Besides therapeutic benefits, early
diagnosis will provide genetic counseling for the family members. Within this context, an extended family with multiple
consanguineous marriages and affected individuals, who presented with combined immune deficiency (CID) and/or Hodgkin
lymphoma phenotype, were examined by exome sequencing. A pathogenic homozygous missense CD70 variation was detected
(NM_001252.5:c332C>T) in concordance with CD70 phenotype and familial segregation was confirmed. CD70 variations in
patients with CID and malignancy have very rarely been reported. This paper reports extended family with multiple affected
members with CID and malignancy carrying a missense CD70 variation, and reviews the rare cases reported in the literature.
Primary immune deficiencies appear to be a potential cause for pediatric cancers. Better focusing on these inborn disorders to
prevent or make an early diagnosis of malignant transformation and reduce mortalities is important.
Keywords CD70 . immune deficiency . lymphoma . EBV .malignancies
Introduction
The last decade has seen an enormous increase in research on
genetic susceptibility to childhood cancer, which has led to
many important insights. Germline components of cancer pre-
disposition showed that up to 10% of children and adolescents
with cancer are associated with inherited mutations.
Identification of germline alterations is very important for
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testing the family members at risk and surveillance. A variety
of genetic disorders lead to increased risk for cancer develop-
ment including Down syndrome, RASopathies, chromosome
breakage syndromes, and primary immune deficiencies [1].
Up to date several genes (such as ITK [2–4], SH2D1A [5],
MAGT1 [6–8], CTPS1 [9], CD27 [10], CD70 [11–13],
CORO1A [14, 15], RASGRP1 [15–17], TNFRSF9 [18],
STK4 [19, 20], CARMIL2 [21–23], and PRKCD [24, 25])
were found to be associated with immunodeficiency and pre-
disposition to EBV-induced lymphoma [26–29]. Recently, an
autosomal recessive combined immunodeficiency (CID) phe-
notype associated with EBV-induced malignancy has been
described as a result of rare CD70 gene variations [11–13].
CD70 is a member of tumor necrosis factor superfamily
(TNFS) and the ligand for CD27 [30, 31]. Co-activation of
CD27 and CD70 regulates the survival, function, and differ-
entiation of T, B, NK, and plasma cells [32–36]. In the CID
patients and mouse models, disruption of CD27-CD70
showed impaired memory responses against different viruses
[37, 38]. Moreover, co-activation of CD27-CD70 on B cells
triggers plasma cell formation and increased IgG production
[39]. CD70 expression is not restricted to healthy activated T
and B cells but also is found to be expressed in different
hematological cancers including lymphomas [40], chronic
lymphocytic leukemia (CLL) [41], and multiple myelomas
(MM) [42]. Here, we describe a homozygous CD70 mutation
in a family with many affected individuals with immunodefi-
ciency and malignancies.
Patients and Methods
Patients
Hereby, we present a family with multiple consanguineous
marriages and individuals affected with lymphoma and/or im-
mune deficiency (Fig. 1 and Table 1). Two siblings diagnosed
with Hodgkin’s lymphoma (HL) and whose parents had a
consanguineous marriage were referred to our center for fur-
ther evaluation and treatment.
The first sibling (V-1) was diagnosed with stage IIIsB
Hodgkin lymphoma of nodular sclerosing histopathology, at
18 months of age in the local university hospital in the
Northeastern part of Turkey. Treatment had been initiated
with two courses of chemotherapy consisting of vincristine,
etoposide, prednisone, and doxorubicin (OEPA), as per the
Euronet-Pediatric Hodgkin Lymphoma-C1 protocol after
which a partial remission was attained and he was referred
to our center. Treatment continued with the same protocol,
with four additional courses of cyclophosphamide, vincristine,
procarbazine, prednisone (COPP) chemotherapy. He experi-
enced a relapse right after the sixth course. He received three
courses of chemotherapy consisting of ifosfamide, etoposide,
carboplatinum (ICE) with a complete response followed by
high dose chemotherapy and autologous stem cell transplan-
tation. He had a second relapse after 3 months, was treated
with targeted therapy (antiCD30 monoclonal antibody-
brentuximab) and ICE, and he achieved complete response.
Treatment continued with radiotherapy. He is under follow-up
for 52 months since diagnosis of HL and with no evidence of
disease. Due to recurrent infections and history of consanguin-
eous marriage in the family, the immunological evaluation
revealed a severe CD4 T cell lymphopenia, which was
thought to be compatible with combined immune deficiency
(Table 1). Allogeneic hematopoetic stem cell transplantation
has been performed when a fully matched unrelated donor
was found (Table 2).
The second sibling (V-3), at 3 years of age, was diagnosed
with stage IIIsB Hodgkin lymphoma of mix cellular histopa-
thology in the local university hospital in the Northeastern part
of Turkey and was referred to our center for further evaluation
and treatment at the same time as her brother who had expe-
rienced a relapse of Hodgkin lymphoma (V-1). Treatment was
initiated with two courses of chemotherapy consisting of cy-
clophosphamide, vincristine, procarbazine, prednisone/doxo-
rubicin, bleomycin, vinblastine (COPP/ABV) chemotherapy,
as per our institutional protocol [43], after which a partial
remission was attained. Treatment continued with the same
protocol, with four additional courses of COPP/ABV chemo-
therapy. She experienced a relapse right after the sixth course.
She received three courses of chemotherapy consisting of
ifosfamide, etoposide, and carboplatinum (ICE) with a com-
plete response followed by high dose chemotherapy and
Fig. 1 Five generations of the pedigree with the index V-3. Indicated
numbers within circles and squares are number of individuals, who
were reported not having any clinical phenotypes
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autologous stem cell transplantation. Due to severe recurrent
infections and history of consanguineous marriage in the fam-
ily, combined immunodeficiency was suspected and she
underwent an allogeneic transplantation from the mother,
who was a full match donor, 29 months after termination of
treatment for HL. Fludarabine and treosulfan were used as
conditioning regimen; lymphocyte engraftment was achieved
at day 21 post-transplant. Full donor chimerism in both total
and T cell was achieved. Cyclosporin A and post-transplant
cyclophosphamide were used for graft versus host (GvHD)
prophylaxis. Grade 2 chronic skin GvHD was observed at
9 months post-transplant, which responded to steroids (which
is tapered) and post-transplant cyclophosphamide. Her
Karnofsky/Lansky performance score is 100. She is under
follow-up for 48 months since diagnosis of HL and with no
evidence of disease.
On family history, another sibling (V-2) had died of infec-
tion at 40 days of age. Soon after the two siblings’ (V-1 and
V-3) referral to our center, a 14-year-old female relative (IV-
10) was referred to our center with encephalitis due to HSV1
infection and recurrent pneumonia. The family history re-
vealed that the siblings of the patient (IV-10) were previously
diagnosed with HL (IV-7, diagnosed at age 15 and died at 20,
and IV-8, diagnosed at age 12, currently in remission at age
17). Paternal aunt of this patient (whowas also a maternal aunt
of V-1 and V-3) has been diagnosed with endometrium cancer
(III-6).
Due to the diagnosis of HL in two siblings (V-1 and
V-3) born to consanguineous parents, family history of
sibling and cousins with severe infections and malignan-
cies, and recurrent infections, an association with EBV
was suspected, and the level of EBV DNA levels at
admission to our center was found to be significantly
elevated (V-1 43,900 copies/ml; V-3 14,067 copies/ml).
The EBV DNA levels were further elevated at relapse
(V-1 185761; V-3 309,242 copies/ml). An inherited im-
munodeficiency was also suspected and both siblings
were evaluated for immunodeficiency including complete
blood counts; flow cytometry of peripheral blood for
CD3, CD4, CD8, CD45, CD19, and CD16; HLA-DR
Table 2 Transplant-related data of the three patients who underwent hematopoietic stem cell transplant
V1 V3 V4
Age at HSCT 5.5 years 6 years 8 years
Donor source 10/10 matched
unrelated
10/10 mother 10/10 mother
Conditioning regimen Treosulfan/fludarabin Treosulfan/fludarabin Treosulfan/fludarabin
GvHD prophylaxis CsA + MMF +
Post-Tx CyC
CsA + Post-Tx CyC CsA
CD34+ stem cell dose 5.7 × 106/kg 5 × 106/kg 5.4 × 106/kg
Engrafment days Neutrophil: 12 Neutrophil: 13 Neutrophil: 11
Lymphocyte: 18 Lymphocyte: 21 Lymphocyte: 10
Thrombocyte: 10 Thrombocyte: 12 Thrombocyte: 11
Post-tx complications None Grade 2 chronic skin GvHD Grade 3 acute skin and liver GvHD
Follow-up time after
transplant (tr)
3 months 11 months 17 months
Last laboratory
investigations after tr.
At 3rd month At 9th month At 15th month
T cell chimerism 100% 100% 100%
IgG 840 mg/dl 692 mg/dl 583 mg/dl
IgA 54 mg/dl 48 mg/dl 26 mg/dl
IgM 92 mg/dl 110 mg/dl 121 mg/dl
CD3% 93 59 68
CD4% 5 29 19
CD8% 80 22 46
CD19% 0.2 19 5
CD16+56% 4 11 16
Ongoing treatments Prophylactic
antimicrobials-CsA
Prophylactic antimicrobials-prednisolon (for
2 months, now tapering)*
Prophylactic antimicrobials-CsA prednisolon (for
10 months, now tapering)
*Cyclosporin A was given for 9 months as GvHD prophylaxis and was stopped. After 2 months, GvHD recurred and responded to prednisolone,
cyclosporin A was not given again. 2 mg/kg/day prednisolon was started as initial dose; if there is a response after 2 weeks, the dose was tapered by 10–
25% every 2 weeks according to maintenance of response
J Clin Immunol
counts; and IgG, IgA, and IgM levels (Table 1). Both
had severe CD4 T cell lymphopenia and low immuno-
globulin levels and were diagnosed with combined im-
munodeficiency (Table 1). In both siblings, immunoglob-
ulin replacement and prophylactic antibiotics were initi-
ated. In both patients EBV DNA levels were negative
(values below 100 copies/ml were considered normal)
after allogeneic stem cell transplantation.
Index patients’ parents and the 6-year-old brother
(V-4) who had cervical lymphadenomegalies were also
evaluated. The brother (V-4) was also found to have
elevated EBV DNA levels (47,566 copies/ml) and was
also diagnosed with combined immune deficiency
(Table 1). There was no malignancy in the excisional
biopsy of the enlarged lymph nodes. He underwent an
allogeneic transplantation from the mother, who was a
full match donor, 15 months after diagnosis of CID.
Fludarabine-treosulfan was used as conditioning regi-
men. Cyclosporin A was given for graft versus host
(GVHD) prophlaxis. He achieved lymphocyte engraft-
ment on day 10 with donor chimerism of 100%, respec-
tively. He developed grade 2 acute GVHD with skin and
liver involvement in the second month of transplantation,
which responded to steroids. The GvHD recurred at
11 months post-transplant and responded to steroids.
He is clinically well for 12 months since allogeneic
transplantation with Karnofsky/Lansky performance
score of 100. His EBV DNA levels were also negative
after the allogeneic SCT.
The first sibling (V1) diagnosed with CID and HL,
underwent allogeneic stem cell transplantation from the
matched unrelated donor 51 months after diagnosis and
37 months after the termination of treatment for relapsed
HL. He did not experience a further relapse before the trans-
plantation. Fludarabine-treosulfan was used as conditioning
regimen. Cyclosporin A and post-transplant cyclophospha-
mide were given as graft versus host (GVHD) prophlaxis.
He achieved lymphocyte engraftment on day 14 with full
donor chimerism on the first month of transplantation. Now,
he is at the third month after transplantation and there is no
evidence of GvHD. All three siblings are clinically well with
IVIG replacement and prophylactic antibiotics, V-1 for
52 months, V-3 for 48 months since diagnosis of HL, and
V-4 for 27 months since diagnosis of CID. After transplanta-
tion, IVIG replacement was given to all three patients for three
to four times when the IgG level was < 400 mg/dl. Transplant-
related data of the three patients who underwent allogeneic
hematopoietic stem cell transplantation are presented in
Table 2.
All analyses were performed after the approval of Istanbul
University Medical Faculty Ethical Board; written and oral
informed consents were taken from the family members or
legal representatives.
Exome Sequencing
Peripheral blood of the patients at remission and healthy indi-
viduals were obtained (denoted with asterisk (* or **) in ped-
igree in Fig. 1) and DNA was isolated with column-based
method of QIAamp DNA Blood Mini kit according to the
manufacturer’s instructions. Quantity and purity of DNA sam-
ples were assessed with spectrophotometry.
A whole exome sequencing (WES) approach was per-
formed by using Agilent SureSelect Human All ExonV6 kit
for exome capturing. Illumina’s raw data was aligned to hg19
reference genome with BWA and SAMtools to generate final
BAM file and variant list. For the selection of candidate genes,
whole variant list was filtered, where intronic and synony-
mous variant were left out. Remaining variants were priori-
tized according to their MAF (< 0.01, reported by
1000Genomes, ExAC, and gnomAD). For the clinical inter-
pretation of candidate variants OMIM, ClinVar’s known re-
ports (benign/pathogenic/uncertain), PolyPhen’s and SIFT’s
predictions, and conservation scores (CADD) were evaluated.
Sanger sequencing was used to validate and familial segrega-
tion analysis was performed for the candidate variations.
Kappa Deleting Excision Circle Analysis
Kappa deleting excision circle (KREC) analysis was per-
formed to homozygous mutation carriers (V-1, V-3, and
V-4), heterozygous parents (IV-3 and IV-4), and age-
matched healthy controls. All KREC analyses were performed
during remission and after autologous bonemarrow transplan-
tations for V-1 and V-3. KREC copy numbers were detected
by quantitative real-time PCR (qRT-PCR) assay on a LC96
real-time PCR System (Roche USA). TRAC gene was used as
housekeeping gene. Primers, probes, and PCR conditions
were previously described [44].
Results
Variants revealed by exome sequencing of index (V-3) were
filtered in the following order: exonic and splice sites, non-
synonymous, homozygous, and finally to variants with MAF
< 0.01 and all identified candidate variants were given in
Supplementary Table 1. Among the genes, which are known
to be associated with immunodeficiency and predisposition to
EBV-associated lymphoma, we have identified a homozy-
gous missense variation in the CD70 and a non-synonymous,
heterozygous exonic variant in ITK with MAF < 0.01
(rs17054374), which is reported in ClinVar as having conflict-
ing interpretation (uncertain significance and benign).
Additional homozygous variations were also identified in
COL5A3, UACA, and USP17L10 genes which are predicted
as disease causing, probably damaging, and deleterious
J Clin Immunol
according to 3 different prediction tools (Mutation Taster,
PolyPhen and SIFT). There is no ClinVar or OMIM pheno-
type data for those genes. Germline UACA loss-of-function
variations were previously reported in one study in colorectal
cancer [45], COL5A3 variants were reported as genetic risk
factor for autism spectrum disorder [46], and USP17L10 gene
variation was classified as variant unknown significance
(VUS). CD70 variation is the strongest candidate among the
others fulfilling the clinical presentation that was previously
reported and suited recessive inheritance pattern. This mis-
sense variation (NM_001252.5:c332C>T) was previously
identified (rs1378830614) with a frequency of 7.95577e−06
(2/251390, heterozygous in two individuals) and presented in
gnomAD database. No previous association was reported
about the functional impact or clinical outcome of the varia-
tion. Familial segregation analysis confirmed all siblings as
homozygous and parents as heterozygous for the CD70 mu-
tation (Fig. 2a). Mother’s (IV-4) cousin (IV-10) was also ho-
mozygous for this mutation.
In silico prediction tools predict as probably damaging
(Polyphen) and deleterious (SIFT) and the position is widely
conserved between the species. This nucleotide is highly con-
served (CADD scores of 25.8) and its amino acid is located in
the extra cytoplasmic TNF domain of CD70 protein that is the
region that CD70 interacts with CD27 (Fig. 3a–c).
KREC analysis carried out in affected homozygous pa-
tients (V-1, V-3, and V-4), heterozygous parents (IV-3 and
IV-4), and healthy controls. The results showed that patients
with immune deficiency and EBV-associated HL (V-1 and
V-3) showed much higher KREC copies (197,893 copies
and 168,269 copies, respectively) compared with heterozy-
gous parents (IV-3: 22,000 copies and IV-4: 25,900 copies)
and healthy controls childhood average count 29,900 copies
(max count 98,000 copies) and adult average count 5290 (max
count 29,100 copies) (Fig. 2b). V-4 who did not develop HL
but only had immune deficiency had KREC copy numbers
(35,832 copies) comparable with parents and healthy controls.
Discussion
Increased risk of cancer development in immune deficient
patients has been acknowledged previously [47–52]. A study
conducted on 3658 primary immunodeficiency patients in the
USIDNET cohort reported a cancer incidence of 4.7%, of
which 48%were diagnosed with lymphoma, 15% skin cancer,
8% genitourinary cancer, 8% gastrointestinal, 6% breast can-
cer, 5% endocrine cancer, 4% head and neck cancer, 3% lung
cancer, 1% bone cancer, and 2% cancers with unspecified
origin [51, 52].
Several primary immune deficiencies have high predispo-
sition to malignancies, especially to EBV-associated lympho-
proliferative disorders due to the impaired anti-viral response.
Germline mutations in genes SH2D1A, ITK, MAGT1,
CORO1A, CD27, CD70 , CTPS1, TNFRSF9, STK4,
CARMIL2 PRKCD, and RASGRP1 are associated with a high
incidence of EBV-associated lymphomas [26–29].
CD27 and CD70 are TNF family members and function as
homodimer type I and homotrimer type II membrane proteins,
respectively [30]. CD70-CD27 pathway is very important for
immune surveillance of B cells and T cell immune function.
CD27 is highly expressed in T cells and some B cells and acts
as co-stimulatory molecule of T cell activation (Fig. 3b) [35,
53]. CD70 is expressed only in a small fraction of B cells.
CD70’s expression is highly upregulated on activated B cells
and EBV-infected B cells. When CD27 on T cells or CD70 on
B cells have defects and impair the CD27-CD70 axis, anti-
viral response of T cells toward EBV-infected cells is im-
paired which in turn leads to lymphoproliferative disorder
[13]. All of the previously reported mutation sites, including
our report, are located in the extracellular domain of CD70,
which might explain the association with immune deficiency
and impaired response to EBV (Fig. 3a).
Up to date six cases with CID and/or EBV-related
Hodgkin’s lymphoma with CD70 mutation have been report-
ed. Caorsi et al. reported CD70mutation in a case with EBV-
Fig. 2 a Sanger validation of
NM_001252.5:c.332C>T
mutation. b KREC copy numbers
in homozygous mutant,
heterozygous and homozygous
wild type individuals. Each
patient’s sample was studied in
technical replicates and the results
were compared with the age-
matched controls both for
childhood and adults
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positive recurrent infections and without leukemia or lympho-
ma development [12]. Abolhassani et al. reported two separate
families with two different CD70 variations: in the first fam-
ily, patients with CD70 mutations had presented with viral
encephalitis or immune deficiency or EBV-associated HL,
and in the second family, two patients were diagnosed with
immune deficiency and EBV-positive HL [11]. Izawa et al.
also reported a case with immune deficiency and EBV-
positive HL [13].
In the present study, four members of a family were iden-
tified with CD70 homozygous mutations; two had combined
immunodeficiency, high titers of EBV DNA, and HL
(V-1)(V-3); one was diagnosed with immune dysregulation
(V-4); and one who had encephalitis and recurrent infections
(IV-10) is being investigated for immunodeficiency. Apart
from our case (V-10), only one patient with CD70 deficiency
is reported with viral encephalitis although the causative agent
is not known in the latter [11]. The patients described till now
are either presented with recurrent infections including severe
viral infections suggesting a combined immune deficiency or
with immune dysregulation and especially malignancy. The
susceptibility to EBV is remarkable, whereas varicella pneu-
monia and herpes simplex encephalitis were also noted [11].
Laboratory evaluations of the patients in the literature varied
from normal to decreased T cells, decreased T and B cells,
and/or abnormal antibody responses. So far, we do not have
data suggesting dysgammaglobulinemia following EBV in-
fections like in X-linked lymphoproliferative syndrome
[11–13].
All reported CD70 mutated patients who developed lym-
phoma had specifically Hodgkin lymphoma. Approximately
40% of Hodgkin lymphomas are associated with EBV infec-
tions with the predominance of mixed cellularity subtype [54].
EBV is thought to serve as an anti-apoptotic functionary to
provide the escape of BCR-negative Hodgkin-Reed-Sternberg
cells from the immune surveillance [55]. The origins of
Hodgkin lymphoma are not fully elucidated and the prefer-
ence for the HL in the case of germline CD70 mutations may
be an interesting matter to focus. CD70 may play a role spe-
cifically in these BCR-negative Hodgkin-Reed-Sternberg
cells.
Kappa deleting excision circles are DNA segments gener-
ated in B cells during their maturation in the bone marrow.
These segments are unable to replicate and consequently are
diluted following cell divisions. Thus, KRECs can be used as
a diagnostic tool in evaluating new lymphocyte output [56].
Until now, KREC measures were not reported in lymphoma
patients. In this study, we found higher KREC levels in ho-
mozygous CD70 deficient patients who developed lympho-
ma. Interestingly, the other affected patient without lymphoma
diagnosis showedKREC levels similar to healthy controls and
heterozygous carriers. Kappa deleting excision circles occur
during T cell–independent phase of B cell development in the
bone marrow and are generated during the maturation from
large pre B II cells to small pre B II cells [56]. Izawa et al.
suggested that CD70 expressed on B cells might act as a
signaler in the case of abnormal B cell proliferation to T cells.
Additionally, somatic CD70 mutations are found in B cell
lymphomas, especially diffuse large B cells and Burkitt’s lym-
phoma [57–59]. Thus, we may speculate that CD70 deficien-
cy may result in abnormal B cell development following EBV
encountering and leading to development of lymphoma. The
normal KREC levels in patient V-4 may support this hypoth-
esis. On the other hand, the samples were drawn following
autologous transplantation for V-1 and V-3, which may also
reflect the reconstitution of B cells. Nevertheless, this finding
needs further investigations and is weak due to lack of inade-
quate number of patient data.
Fig. 3 a Schematic view of CD70
protein and previously reported
mutations, b schematic view of T
cell and antigen presenting cell’s
(APC) interaction. c NM_
001252.5:c332C conservation
across vertebrae (base G with
gray underline)
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Exome sequencing has an advantage in identifying
disease-causing gene(s) especially in a heterogeneous
disease group such as immune deficiency and cancer
predisposition syndromes with long and growing list of
genes. In this study, exome sequencing has enabled us
to identify the CD70 mutation in multiple family mem-
bers with immunodeficiency and malignancies. We were
able to identify the homozygous mutation in three sib-
lings and the heterozygous mutation in both parents and
a homozygous mutation in a distant cousin. The identi-
fication of this mutation has also implications for sur-
veillance of other family members. Unfortunately, de-
spite many communications, the second family
consented for the analysis of only the child who had
had life-threatening infection (encephalitis); they are fur-
ther referred for clinical surveillance in the center in
their local setting.
Although autologous stem cell transplantation is a known
treatment option in recurrent Hodgkin lymphoma, in patients
with immune deficiency, allogeneic stem cell transplantation
is recommended. Thus, consanguineous marriages, history of
recurrent infections in the family, or family history of HL
should alert the physician for immune deficiency. Two of
the patients in this study (V1 and V3) had undergone autolo-
gous stem cell transplantation for relapsed Hodgkin
Lymphoma prior to the diagnosis of immune deficiency and
CD70 mutation.
In conclusion, primary immune deficiency patients are
predisposed to malignancies, especially lymphomas [60].
CD70 mutation has rarely been reported in CID and/or
Hodgkin lymphoma. In families with consanguineous mar-
riages, with family history of recurrent or severe infections,
or family history of HL, especially if multiple members are
affected, individuals should be investigated for EBV DNA
levels, immune deficiency, and CD70 mutation.
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